ARGX vs INSM vs ALNY Stock Comparison

Argenx Se, Insmed and Alnylam Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.18B
P/E
31.0x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$26.90B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

10 decided of 12

Argenx Se leads on 4 of the 12 questions below (Argenx Se 4, Alnylam Pharmaceuticals 4, Insmed 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARGXINSMALNYLeader
Larger companyMarket capitalisation $58.18B $26.90B $21.33B ARGX
Cheaper on earningsLower P/E, profitable companies only 31.0x -44.4x 8.1x ALNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.8x — 8.6x ALNY
Faster revenue growthRevenue growth, trailing twelve months +61.5% +240.0% +60.8% INSM
More profitableNet margin, trailing twelve months 32.3% -39.9% 52.8% ALNY
Better return on capitalReturn on invested capital — -41.1% — –
Less leveragedLower net debt / EBITDA — 1.1x -3.1x ALNY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.7% -36.6% -63.6% ARGX
Better 5-year returnAnnualised price return, 5 years +25.4%/yr +30.6%/yr -0.7%/yr INSM
Less volatileAnnualised volatility, 1 year 37.7% 62.2% 59.1% ARGX
Higher overall scoreMean of the five percentile scores vs peers 92/100 66/100 81/100 ARGX

Percentile Scorecard

ARGXINSMALNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARGXINSMALNY
Valuation 82 #122 of 660 70 #201 of 660 91 #61 of 660
Growth 96 #27 of 619 85 #91 of 619 99 #10 of 619
Profitability 99 #9 of 595 69 #186 of 595 91 #55 of 595
Financial Health – 37 #428 of 683 61 #269 of 683
Shareholder Returns – 67 #153 of 459 66 #156 of 459
Overall 92 66 81
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ALNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARGXINSMALNYSPY
1 month +17.3%+23.9%-26.5% -2.0%
3 months +12.8%-2.1%-27.8% -2.8%
6 months +20.1%+11.0%-42.5% +2.0%
Year to date +14.2%-30.4%-58.5% +10.6%
1 year +7.7%-36.6%-63.6% +12.2%
3 years +96.0%+393.7%-2.9% +68.1%
3 years, per year +25.2%+70.3%-1.0% +18.9%
5 years +210.1%+280.3%-3.4% +61.4%
5 years, per year +25.4%+30.6%-0.7% +10.1%
10 years —+738.5%+254.6% +248.5%
10 years, per year —+23.7%+13.5% +13.3%

Risk

MeasureARGXINSMALNYSPY
Volatility, 1Y 37.7%62.2%59.1% 13.6%
Downside volatility, 1Y 35.2%61.0%74.1% 13.9%
Beta vs S&P 500, 1Y 0.540.550.50 1.00
Return / volatility, 1Y 0.20-0.59-1.08 0.90
Max drawdown, 5Y -38.2%-56.5%-69.1% -25.4%
From 52-week high -9.3%-42.7%-65.1% -3.2%
52-week high $1,058.90$211.41$473.29 $779.14
52-week low $663.93$91.88$151.64 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARGXINSMALNY
P/E now vs peer median 31.4xmedian 17.0x -43.8xmedian 17.0x 8.3xmedian 17.0x
P/S now vs peer median 10.2xmedian 8.4x 17.5xmedian 8.4x 4.4xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x -48.6xmedian 14.6x 18.3xmedian 14.6x
P/FCF now vs peer median —median 19.0x -42.3xmedian 19.0x 27.4xmedian 19.0x
P/B now vs peer median —median 2.0x 36.6xmedian 2.0x 6.1xmedian 2.0x
PEG now vs peer median 0.30median 0.43 -2.40median 0.43 0.09median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARGXINSMALNY
Revenue $5.82B $1.52B $5.01B
Gross profit $5.24B $1.28B $3.88B
Operating income $1.74B -$563.99M $977.59M
Net income $1.88B -$605.67M $2.65B
Free cash flow – -$627.58M $806.31M
R&D $1.80B $944.39M $1.56B
EPS (diluted) $28.43 $-2.77 $19.19
Cash & equivalents – $396.60M $1.75B
Total debt – $555.09M $361.53M
Shares (diluted) 66.03M 218.79M 138.04M
Enterprise value $58.18B $21.94B $8.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARGXINSMALNY
P/E 31.4x -43.8x 8.3x
P/FCF – -42.3x 27.4x
P/Operating cash flow – -44.6x 23.1x
P/S 10.2x 17.5x 4.4x
P/B – 36.6x 6.1x
P/Tangible book – 45.2x 6.1x
EV/EBITDA – -48.6x 18.3x
EV/EBIT 34.1x -46.1x 19.3x
EV/Revenue 10.2x 17.1x 3.8x
EV/FCF – -41.4x 23.4x
EV/Operating cash flow – -43.6x 19.7x
PEG (3Y EPS CAGR) 0.30 -2.40 0.09

Growth

14 metrics
MetricARGXINSMALNY
Revenue growth (1Y) 61.5% 240.0% 60.8%
Revenue CAGR (3Y) 80.5% 75.6% 42.7%
Gross profit growth (1Y) 62.2% 274.9% 49.6%
Gross profit CAGR (3Y) 80.0% 79.8% 37.8%
Operating income growth (1Y) 120.6% 51.3% 269.3%
Operating income CAGR (3Y) 85.1% 6.2% 68.2%
Net income growth (1Y) 22.5% 48.8% 2,137%
Net income CAGR (3Y) 115.5% 5.8% 93.1%
EPS growth (1Y) 20.9% 50.5% 2,126%
EPS CAGR (3Y) 104.8% 18.2% 90.8%
Operating cash flow growth (1Y) – 32.6% 351.6%
Operating cash flow CAGR (3Y) – -5.4% 685.4%
Free cash flow growth (1Y) – 30.7% 382.3%
Free cash flow CAGR (3Y) – -6.2% 141.7%

Profitability

14 metrics
MetricARGXINSMALNY
Gross margin 90.0% 84.4% 77.4%
EBITDA margin – -35.1% 20.6%
Operating margin 29.9% -37.1% 19.5%
Pretax margin 32.6% -39.4% 15.6%
Net margin 32.3% -39.9% 52.8%
FCF margin – -41.3% 16.1%
Operating cash flow margin – -39.2% 19.1%
Return on equity – -81.9% 106.4%
Return on assets – -28.1% 38.9%
Return on invested capital – -41.1% –
Return on capital employed – -36.0% 20.7%
Asset turnover – 0.7x 0.7x
Cash conversion (OCF / net income) – 1.0x 0.4x
Stock comp / revenue – 11.0% 6.1%

Financial Health

11 metrics
MetricARGXINSMALNY
Debt / assets – 24.9% 4.5%
Debt / equity – 0.8x 0.1x
Net debt / EBITDA – 1.1x -3.1x
Debt / FCF – -0.9x 0.4x
Liabilities / assets – 67.4% 54.9%
Equity / assets – 32.6% 45.1%
Interest coverage 10,120x -5.5x 3.2x
Current ratio – 2.9x 2.5x
Quick ratio – 2.4x 2.3x
Cash ratio – 1.9x 1.7x
Altman Z-score – 7.36 3.78

Shareholder Returns

7 metrics
MetricARGXINSMALNY
Dividend yield – – –
Net buyback yield – -0.4% -0.5%
Shareholder yield – -0.4% -0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARGXINSMALNY
Forward P/E 32.8xFY2026 – 8.6xFY2026
EPS, next fiscal year $29.27FY2026 $-1.68FY2026 $19.15FY2026
EPS growth, next FY +49.6%FY2026 – +721.9%FY2026
EPS growth, the year after +32.0% – -56.0%
Revenue, next fiscal year $6.16BFY2026 $1.99BFY2026 $5.65BFY2026
Revenue growth, next FY +44.9%FY2026 +227.7%FY2026 +52.2%FY2026
Revenue growth, the year after +24.0% +59.5% +23.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARGXINSMALNY
Held by institutions 46.1% 100.0% 99.7%
Institutions holding 506 671 788
Change in shares held, QoQ -2.0% +3.4% +3.8%
Institutions buying 263 369 412
Institutions selling 162 230 279
Buyers to sellers 1.62 1.60 1.48

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARGXINSMALNY
ARGX 1.00 0.27 0.15
INSM 0.27 1.00 0.02
ALNY 0.15 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARGX, INSM and ALNY?

Argenx Se (ARGX) is the largest by market capitalisation: Argenx Se (ARGX) $58.18B, Insmed (INSM) $26.90B, Alnylam Pharmaceuticals (ALNY) $21.33B.

Which stock is cheaper, ARGX, INSM and ALNY?

Alnylam Pharmaceuticals (ALNY) trades on the lowest price-to-earnings ratio (Argenx Se (ARGX) 31.0x, Insmed (INSM) -44.4x, Alnylam Pharmaceuticals (ALNY) 8.1x). On next year's consensus earnings, Alnylam Pharmaceuticals (ALNY) is cheapest (Argenx Se (ARGX) 32.8x, Alnylam Pharmaceuticals (ALNY) 8.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Argenx Se (ARGX) +61.5%, Insmed (INSM) +240.0%, Alnylam Pharmaceuticals (ALNY) +60.8%.

Which company is more profitable?

Alnylam Pharmaceuticals (ALNY) has the highest net margin (Argenx Se (ARGX) 32.3%, Insmed (INSM) -39.9%, Alnylam Pharmaceuticals (ALNY) 52.8%).

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Argenx Se (ARGX) +7.7%, Insmed (INSM) -36.6%, Alnylam Pharmaceuticals (ALNY) -63.6%. Over five years, Insmed (INSM) compounded fastest (Argenx Se (ARGX) +25.4%/yr, Insmed (INSM) +30.6%/yr, Alnylam Pharmaceuticals (ALNY) -0.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Argenx Se (ARGX) has been the steadiest (Argenx Se (ARGX) 37.7%, Insmed (INSM) 62.2%, Alnylam Pharmaceuticals (ALNY) 59.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARGX, INSM and ALNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.